Abstract:

Pituitary adenoma is a common primary tumor in central nervons system. The aggressive pituitary adenomas show invasive characteristics with higher recurrence rate and worse prognosis, which normally need the comprehensive therapy of surgery, radiotherapy and chemical medications. The therapy of aggressive pituitary adenomas by temozolomide and whether O⁶-methylguanine-DNA methyltransferase (MGMT) could predict the curative effect of temozolomide have become hot spots in recent years. This review intends to illustrate the advance of the therapy of aggressive pituitary adenomas by temozolomide.

Key words: Pituitary neoplasms, Temozolomide (not in MeSH), O (6) - methylguanine - DNA methyltransferase, Review

摘要：

垂体腺瘤是临床常见的原发性中枢神经系统肿瘤，其中侵袭性腺瘤和垂体腺癌因其侵袭性生长的病理生理学特点仍是目前神经外科治疗之难点，需手术切除病灶辅助放射治疗和药物化疗。近年来，由于替莫唑胺对功能性垂体腺瘤、侵袭性垂体腺瘤和垂体腺癌的治疗取得进展，使其颇受临床关注，尤其是O⁶-甲基鸟嘌呤-DNA 甲基转移酶可否作为判断替莫唑胺疗效的指标，成为烷化剂化疗药物之研究热点。

关键词: 垂体肿瘤, 替莫唑胺（非MeSH 词）, O（6）-甲基鸟嘌呤DNA 甲基转移酶, 综述